Efficacy and tolerability of a standardized herbal product from Galphimia glauca on generalized anxiety disorder. A randomized, double-blind clinical trial controlled with lorazepam

Planta Medica

Volumn 73, Issue 8, 2007, Pages 713-717

  Herrera Arellano, Armando ^a   Jiménez Ferrer, Enrique ^a   Zamilpa, Alejandro ^a   Morales Valdéz, Marisol ^a   García Valencia, Claudia E ^a   Tortoriello García, Jaime ^a  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

Anxiolytic, lorazepam; Galphimia glauca; Galphimine B; Generalized anxiety disorder (GAD); Malpighiaceae; Plant derived medicine

Indexed keywords

GALPHIMIA GLAUCA EXTRACT; HERBACEOUS AGENT; LORAZEPAM; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GALPHIMIA GLAUCA; GENERALIZED ANXIETY DISORDER; HAMILTON ANXIETY SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICINAL PLANT; RANDOMIZED CONTROLLED TRIAL; SEDATION; SIDE EFFECT; TRANQUILIZING ACTIVITY; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; DOUBLE-BLIND METHOD; FEMALE; GALPHIMIA; HUMANS; LORAZEPAM; MALE; MIDDLE AGED; PHYTOTHERAPY; PLANT EXTRACTS; TREATMENT OUTCOME;

GALPHIMIA GLAUCA; MALPIGHIACEAE;

EID: 34547809446     PISSN: 00320943     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-981539     Document Type: Article

References (29)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, fourth edition, text revision. Washington DC: American Psychiatric Association; 2000: 472-6.
2. Kessler RC, Brandenburg N, Lane M, Roy-Byrne P, Stang PD, Stein DJ et al. Rethinking the duration requirement for generalized anxiety disorder: evidence from the National Comorbidity Survey Replication. Psychol Med 2005; 35: 1073-82.
3. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51: 8-19.
4. Couvee JE, Zitman FG. The benzodiazepine withdrawal symptom questionnaire: psychometric evaluation during a discontinuation program in depressed chronic benzodiazepine users in general practice. Addiction 2002; 97: 337-45.
5. Rickels K, Schweizer E, DeMartinis N, Mandos L, Mercer C. Gepirone and diazepam in generalized anxiety disorder: a placebo-controlled trial. J Clin Psychopharmacol 1997; 17: 272-7.
6. Llorca PM, Spadone C, Sol O, Danniau A, Bougerol T, Corruble E et al. Efficacy and safety of hydroxyzine in the treatment of generalized anxiety disorder: a 3-month double-blind study. J Clin Psychiatry 2002; 63: 1020-7.
7. Bielski RJ, Bose A, Chang CC. A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder. Ann Clin Psychiatry 2005; 17: 65-9.
8. Feltner DE, Crockatt JG, Dubovsky SJ, Cohn CK, Shrivastava RK, Targum SD et al. A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol 2003; 23: 240-9.
9. Martínez M. Las plantas medicinales de Mexico, 5th edition. Mexico: Andres Botas; 1969: 402-3.
10. Estrada E. Jardín botánico de plantas medicinales. Mexico: Universidad Autónoma de Chapingo. Departamento de Fitotécnia; 1985: 15.
11. Tortoriello J, Lozoya X. Effect of Galphimia glauca methanolic extract on neuropharmacological tests. Planta Med 1992; 58: 234-6.
12. Herrera-Ruiz M, Jimenez-Ferrer JE, De Lima TC, Aviles-Montes D, Perez-Garcia D, Gonzalez-Cortazar M et al. Anxiolytic and antidepressant-like activity of a standardized extract from Galphimia glauca. Phytomedicine 2006; 13: 23-8.
13. Herrera-Ruiz M, Gonzalez-Cortazar M, Jimenez-Ferrer E, Zamilpa A, Alvarez L, Tortoriello J et al. Anxiolytic effect of natural galphimines from Galphimia glauca and their chemical derivatives. J Nat Prod 2006; 69: 59-61.
14. Tortoriello J, Ortega A. Sedative effect of galphimine-B, a nor-seco-triterpenoid from Galphimia glauca. Planta Med 1993; 59: 398-400.
15. Toscano RA, Ortega A, Maldonado E, Gaviño R, Lozoya X, Tortoriello J. Structure of galphimine B. Acta Cryst C 1993; 49: 774-6.
16. Tortoriello J, Ortega A, Herrera-Ruiz M, Trujillo J, Reyes-Vázquez C. Galphimine-B modifies electrical activity of ventral tegemental area neurons in rats. Planta Med 1998; 64: 309-13.
17. Prieto-Gomez B, Tortoriello J, Vazquez-Alvarez A, Reyes-Vazquez C. Galphimine B modulates synaptic transmission on dopaminergic ventral tegmental area neurons. Planta Med 2003; 69: 38-43.
18. González-Cortazar M, Tortoriello J, Álvarez L. Norsecofriedelanos as spasmolytics. Advances of structure activity relationships. Planta Med 2005; 71: 711-6.
19. ,9 Aguilar-Santamaría L, Ramírez G, Herrera-Arellano A, Zamilpa A, Jiménez J, Alonso-Cortes D et al. Toxicological and cytotoxic evaluation of standardized extracts of Galphimia glauca. J Ethnopharmacol 2007; 109: 35-40.
20. Rojas G, Aranda E, Navarro V, Zamilpa A, Tortoriello J. In vitro propagation of Galphimia glauca and content of the sedative compound galphimine-B in wild and micropropagated plants. Planta Med 2005; 71: 076-8.
21. Organización Mundial de la Salud. Directrices de la OMS sobre buenas prácticas agrícolas y de recolección (BPAR) de plantas medicinales. Ginebra: Organización Mundial de la Salud; 2003.
22. Comisión permanente de la farmacopea de los estados unidos mexicanos. Farmacopea de los Estados Unidos mexicanos, 8th edition. México: Secretaría de Salud; 2004: 311-572.
23. Alpert JE, Franznick DA, Hollander SB, Fava M. Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder. 2004; 65: 1069-75.
24. Boerner RJ, Sommer H, Berger W, Kuhn U, Schmidt U, Mannel M. KavaKava extract LI 150 is as effective as Opipramol and Buspirone in generalised anxiety disorder - an 8-week randomized, double-blind multi-centre clinical trial in 129 out-patients. Phytomedicine 2003; 10: 38-49.
25. Andreatini R, Sartori VA, Seabra ML, Leite JR. Effect of valepotriates (valerian extract) in generalized anxiety disorder: a randomized placebo-controlled pilot study. Phytother Res 2002; 16: 650-4.
26. Schulze J, Raasch W, Siegers CP. Toxicity of kava pyrones drug safety and precautions - a case study. Phytomedicine 2003; 10: 68-73.
27. Hadley S, Petry JJ. Valerian. Am Fam Physician 2003; 67: 1755-8.
28. Rickels K, Pollack MH, Feltner DE, Lydiard RB, Zimbroff DL, Bielski RJ et al. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry 2005; 62: 1022-30.
29. Goodman WK, Bose A, Wang Q, Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials. J Affect Disord 2005; 87: 161-7.